Travere Therapeutics Ownership | Who Owns Travere Therapeutics?

Overview Forecast RevenueFinancials Chart Transcripts

Travere Therapeutics Ownership Summary

Travere Therapeutics is owned by 111.99% institutional investors, 0.76% insiders. Janus henderson group is the largest institutional shareholder, holding 12.80% of TVTX shares. Delaware Small Cap Core I is the top mutual fund, with 4.42% of its assets in Travere Therapeutics shares.

TVTX Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Travere Therapeutics	111.99%	0.76%	-12.75%
Sector	Healthcare Stocks	35.34%	11.88%	52.77%
Industry	Biotech Stocks	35.37%	11.83%	52.80%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Janus henderson group	11.42M	12.80%	$339.25M
Fmr	10.97M	12.29%	$325.86M
Blackrock	7.64M	9.86%	$62.84M
Blackrock funding, inc. /de	7.79M	8.73%	$231.50M
Vanguard group	6.31M	7.07%	$241.08M
State street	4.96M	5.56%	$147.36M
Armistice capital	4.90M	5.49%	$145.50M
Perceptive advisors	4.14M	4.64%	$123.08M
Macquarie management	3.27M	3.67%	$97.17M
Geode capital management	2.37M	2.66%	$70.41M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Palisades investment partners	255.24K	2.97%	$7.58M
Kynam capital management, lp	1.57M	2.88%	$46.62M
Bioimpact capital	1.13M	2.60%	$33.67M
Rock springs capital management lp	1.48M	2.59%	$43.91M
Armistice capital	4.90M	2.59%	$145.50M
Knott david m jr	140.63K	2.49%	$4.18M
Perceptive advisors	4.14M	2.41%	$123.08M
Superstring capital management lp	102.75K	2.18%	$3.05M
Emerald advisers	1.56M	1.46%	$46.26M
Emerald mutual fund advisers trust	945.03K	1.36%	$28.08M

Top Buyers

Holder	Shares	% Assets	Change
Fmr	10.97M	0.02%	1.35M
Armistice capital	4.90M	2.59%	1.13M
Bioimpact capital	1.13M	2.60%	1.13M
Kynam capital management, lp	1.57M	2.88%	1.05M
Janus henderson group	11.42M	0.17%	908.42K

Top Sellers

Holder	Shares	% Assets	Change
Macquarie group	-	-	-4.98M
Viking global investors lp	-	-	-2.60M
Adage capital partners gp	977.00K	0.04%	-1.95M
Finepoint capital lp	-	-	-1.78M
Morgan stanley	301.65K	0.00%	-1.11M

New Positions

Holder	Shares	% Assets	Change	Value
Bioimpact capital	1.13M	2.60%	1.13M	$33.67M
Vanguard fiduciary trust	612.62K	0.00%	612.62K	$18.20M
Soleus capital management	546.00K	0.66%	546.00K	$16.22M
T. rowe price investment management	520.60K	0.01%	520.60K	$15.47M
Hsbc	396.85K	0.01%	396.85K	$11.79M

Sold Out

Holder	Change
Toronto dominion bank	-3.00
Wealthspire advisors	-4.00
Clearstead advisors	-9.00
Bare financial services	-12.00
Bell investment advisors	-14.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	275	-8.33%	99,905,804	-2.24%	111	0.85%	140	-16.67%	92	-6.12%
Dec 31, 2025	123	-52.69%	33,249,544	-66.99%	37	0.29%	78	-43.48%	36	-52.00%
Sep 30, 2025	97	-54.46%	31,195,759	-67.08%	35	0.31%	55	-52.17%	27	-59.09%
Jun 30, 2025	221	-4.74%	100,360,560	2.40%	112	0.92%	115	-13.53%	71	20.34%
Mar 31, 2025	11	-94.74%	4,535,953	-95.23%	5	0.03%	5	-96.12%	3	-94.12%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Delaware Small Cap Core I	3.45M	4.42%	-21.39K
Strategic Advisers Fidelity US TtlStk	3.54M	3.84%	134.29K
Macquarie Small Cap Core I	3.36M	3.77%	-252.48K
State Street® SPDR® S&P® Biotech ETF	3.19M	3.46%	-31.57K
Vanguard Total Stock Mkt Idx Inv	2.95M	3.19%	124.70K
Aviva Investors GlConvtAbsRet I USD Acc	2.20M	2.88%	-229.35K
Vanguard US Total Market Shares ETF	2.51M	2.82%	-
Nomura US Small Cap Core Equity	2.12M	2.30%	2.12M
Nomura Small Cap Core I	2.12M	2.30%	-67.62K
iShares Russell 2000 ETF	1.94M	2.09%	16.40K

Recent Insider Transactions

Date	Name	Role	Activity	Value
May 15, 2026	Coughlin Timothy	-	Sell	$141.34K
May 05, 2026	Baynes Roy D.	-	Sell	$209.93K
May 04, 2026	Meckler Jeffrey A	-	Sell	$360.00K
May 06, 2026	ROTE WILLIAM E.	Chief Research Officer	Sell	$121.43K
May 05, 2026	REED ELIZABETH E	Chief Legal Officer and GC	Sell	$101.42K

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	-	38
2026 Q1	-	23
2025 Q4	-	12
2025 Q3	-	5
2025 Q2	-	6

TVTX Ownership FAQ

Who Owns Travere Therapeutics?

Travere Therapeutics shareholders are primarily institutional investors at 111.99%, followed by 0.76% insiders and -12.75% retail investors. The average institutional ownership in Travere Therapeutics's industry, Biotech Stocks , is 35.37%, which Travere Therapeutics exceeds.

Who owns the most shares of Travere Therapeutics?

Travere Therapeutics’s largest shareholders are Janus henderson group (11.42M shares, 12.80%), Fmr (10.97M shares, 12.29%), and Blackrock (7.64M shares, 9.86%). Together, they hold 34.96% of Travere Therapeutics’s total shares outstanding.

Does Blackrock own Travere Therapeutics?

Yes, BlackRock owns 9.86% of Travere Therapeutics, totaling 7.64M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 62.84M$. In the last quarter, BlackRock decreased its holdings by -152K shares, a -1.95% change.

Who is Travere Therapeutics’s biggest shareholder by percentage of total assets invested?

Palisades investment partners is Travere Therapeutics’s biggest shareholder by percentage of total assets invested, with 2.97% of its assets in 255.24K Travere Therapeutics shares, valued at 7.58M$.

Who is the top mutual fund holder of Travere Therapeutics shares?

Delaware Small Cap Core I is the top mutual fund holder of Travere Therapeutics shares, with 4.42% of its total shares outstanding invested in 3.45M Travere Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools